-
Mashup Score: 9FDA’s ODAC Votes Against Risk/Benefit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Risk NMIBC - 5 day(s) ago
The FDA’s ODAC voted against the risk/benefit profile of UGN-102 for recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 1Sources: Lakers move for Hornets center Williams - 4 month(s) ago
The Lakers are trading Dalton Knecht, Cam Reddish, a 2031 unprotected first-round pick and a 2030 pick swap to the Hornets for center Mark Williams, sources tell ESPN.
Source: www.espn.comCategories: General Medicine News, Hem/OncsTweet-
Rob Pelinka - hands down the best executive in the league!!! Let’s go Lakers!! https://t.co/6OVSc3LzwL
-
-
Mashup Score: 16Bladder-Sparing Therapies: Risks and Rewards - 5 month(s) ago
Explore the latest advancements in bladder cancer treatment with Dr. Roger Li. Learn about bladder-sparing therapies, patient experiences, and groundbreaking innovations transforming care.
Source: bcan.orgCategories: General Medicine News, Hem/OncsTweet-
Wonderful to chat about bladder sparing therapies with the one and only Rick Bangs! https://t.co/ekvpZX1Oai @BladderCancerUS
-
-
Mashup Score: 16Bladder-Sparing Therapies: Risks and Rewards - 5 month(s) ago
Explore the latest advancements in bladder cancer treatment with Dr. Roger Li. Learn about bladder-sparing therapies, patient experiences, and groundbreaking innovations transforming care.
Source: bcan.orgCategories: General Medicine News, Hem/OncsTweet-
Wonderful to chat about bladder sparing therapies with the one and only Rick Bangs! https://t.co/ekvpZX1Oai @BladderCancerUS
-
-
Mashup Score: 12
Major Finding: A phase 1b trial demonstrated the safety of cretostimogene grenadenorepvec plus nivolumab in muscle-invasive bladder cancer (MIBC).Concept: Boosting immune checkpoint inhibition with oncolytic virotherapy enhanced antitumor immunity in part through tertiary lymphoid structure maturation.Impact: These clinical results warrant further investigation of oncolytic virotherapy and immune checkpoint inhibitors in MIBC.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive Bladder Cancer | Cancer Discovery News | American Association for Cancer Research https://t.co/BMcEE1564h
-
-
Mashup Score: 12Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC - 6 month(s) ago
“Together, the data point to the exciting potential for this combination regimen to be used to treat patients with muscle invasive bladder cancer,” says Roger Li, MD.
Source: www.urologytimes.comCategories: General Medicine News, Hem/OncsTweet-
Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC https://t.co/4OpHOH9WRt via @@urologytimes
-
-
Mashup Score: 12Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC - 7 month(s) ago
“Together, the data point to the exciting potential for this combination regimen to be used to treat patients with muscle invasive bladder cancer,” says Roger Li, MD.
Source: www.urologytimes.comCategories: General Medicine News, Hem/OncsTweet-
Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC https://t.co/4OpHOH9WRt via @@urologytimes
-
-
Mashup Score: 6
A recent phase 3 trial of intravesical nadofaragene firadenovec reported a promising complete response rate for patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. This study examined the ability of antiadenovirus antibody levels to predict the durability of thera …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@eugene_pietzak @MarkTysonMD Same goes for BOND-003. The reasoning being serum anti-adenovirus titers can be generated due to treatment https://t.co/GSLhaxpSH8 @APMitra @VikramNarayan Would be a fascinating question to work out in real practice
-
-
Mashup Score: 10Cretostimogene Grenadenorepvec: A Novel Oncolytic Immunotherapy for BCG-Unresponsive NMIBC - Roger Li - 12 month(s) ago
Zach Klaassen interviews Roger Li about the CORE-001 trial for BCG-unresponsive non-muscle invasive bladder cancer. Dr. Li highlights the significant need for bladder-sparing therapies for patients who are too frail or unwilling to undergo radical cystectomy. The trial explores the combination of cretostimogene grenadenorepvec, an oncolytic immunotherapy, with pembrolizumab. This combination…
Source: www.urotoday.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/sZVg38SgV3 via @urotoday
-
-
Mashup Score: 40KEYNOTE-057: Patients With BCG-Unresponsive NMIBC Who Do Not Respond to Pembro | GU Oncology Now - 12 month(s) ago
Dr. Li describes his post hoc analysis and findings regarding patients with BCG–unresponsive, high-risk NMIBC in KEYNOTE-057.
Source: guoncologynow.comCategories: General Medicine News, Hem/OncsTweet-
KEYNOTE-057: Outcomes for Patients With BCG-Unresponsive NMIBC Who Do Not Respond to Pembrolizumab https://t.co/OYEUFnfPGS
-
FDA’s ODAC Votes Against Risk/Benefit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Risk NMIBC https://t.co/LBIDuoV4yH